Circulating Surfactant Protein-D Is Associated With Clinical Outcomes in Peripheral Artery Disease Patients Following Endovascular Therapy

DOI Web Site Web Site PubMed 参考文献33件
  • Otaki Yoichiro
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Watanabe Tetsu
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Takahashi Hiroki
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Sugai Takayuki
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Yokoyama Miyuki
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Nishiyama Satoshi
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Arimoto Takanori
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Shishido Tetsuro
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Miyamoto Takuya
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Yamanaka Tamon
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Kubota Isao
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Watanabe Masafumi
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

この論文をさがす

抄録

<p>Background:Peripheral artery disease (PAD) is a risk factor for the development of cardiovascular disease and death. Surfactant protein-D (SP-D) is a 43-kDa protein secreted from type II pneumocytes in the lungs. Recent studies have demonstrated that circulating SP-D plays a key role in the development of atherosclerosis and is related to clinical outcomes in patients with ischemic heart disease. However, it remains unclear whether circulating SP-D is associated with clinical outcomes in patients with PAD.</p><p>Methods and Results:We enrolled 364 patients with PAD who underwent endovascular therapy. We measured serum levels of SP-D and Krebs von den Lungen-6 (KL-6). During a median follow-up period of 974 days, there were 69 major adverse cardiovascular and leg events (MACLE), including 48 major adverse cardiovascular events (MACE). Kaplan-Meier analysis demonstrated that patients with high SP-D (≥110 ng/mL) had higher rates of MACE and MACLE than those with low SP-D. Multivariate Cox proportional hazard regression analysis demonstrated that SP-D, but not KL-6, was an independent predictor of MACE and MACLE. The addition of SP-D to known risk factors significantly improved the C index and net reclassification index. The circulating SP-D level was affected by sex, diabetes mellitus, and cilostazol prescription.</p><p>Conclusions:Circulating SP-D was associated with clinical outcomes in patients with PAD, suggesting that it may be a new therapeutic target in these patients.</p>

収録刊行物

  • Circulation Journal

    Circulation Journal 82 (7), 1926-1934, 2018-06-25

    一般社団法人 日本循環器学会

参考文献 (33)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ